研究人员针对 ARID1A 缺陷型卵巢透明细胞癌（OCCC）治疗难题，研究靶向 USP8，发现其可诱导合成致死，有望用于精准治疗。

为探究神经母细胞瘤（NB）“冷肿瘤” 表型成因，研究人员聚焦 ARID1A 与 IFNγ 信号通路，发现 ARID1A 缺失是关键，为免疫治疗提供依据。 研究背景：破解神经母细胞瘤免疫治疗困境的探索之旅 在儿科癌症的世界里，神经母细胞瘤（Neuroblastoma，NB）是一个极为棘手 ...

在这项研究中，作者对来自30名志愿者（包括18名胃癌患者和12名健康个体）的238个胃腺体进行了全基因组测序。胃腺体是胃上皮的基本单位，每个腺体通常由一个干细胞的后代细胞组成，会形成单克隆细胞群。他们发现正常胃腺体细胞每年大约会积累27.8个单核苷酸 ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Nuvectis Pharma, Inc. ("Nuvectis”, "Company”), a biopharmaceutical company focused on the development of innovative precision ...

In this repository is the code to explore ARID1A-driven resistance mechanisms in melanoma treated with BRAF and MAPK inhibitors. This repository contains the code integrating transcriptomics, ...

First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated ...

Laidlaw initiated coverage on shares of Nuvectis Pharma (NASDAQ:NVCT – Free Report) in a report released on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $19.00 price ...

NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored ...